Loading stock data…
AIM
$0.52-0.00 (-0.64%)
Market ClosedLast close May 1
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
AIM in the Healthcare sector is trading at $0.52. The stock is currently near its 52-week low of $0.48, remaining 72.0% below its 200-day moving average. Technical signals show neutral RSI of 48 and bullish MACD crossover, explaining why AIM maintains its current current market pressure. The Whystock Score of 15/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 48) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$0.52
Potential Upside
5%
Whystock Fair Value$0.54
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus1 analysts
Mean target$10.00+1840.6%
Range$10.00 – $10.00
Fundamentals
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. Its flagship products are Ampligen (rinta...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$4.29M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.36
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
213.66%
Volume
Today's trading volume
216,189
Recent News
We Might See A Profit From Aimia Inc. (TSE:AIM) Soon
With the business potentially at an important milestone, we thought we'd take a closer look at Aimia Inc.'s ( TSE:AIM...
Aimia Q4 Earnings Call Highlights
Aimia (TSE:AIM) executives told investors the company’s transformation into what it described as a “useful permanent capital vehicle” advanced in the fourth quarter of 2025, with management highlighting solid operating results in its core businesses, a higher cash balance, and progress toward a plan
Thermo Fisher Scientific (TMO) Partners With AIM ImmunoTech on Phase 3 Cancer Trial
Thermo Fisher Scientific Inc. (NYSE:TMO) is one of the 10 Best Diagnostics and Research Stocks to Buy According to Analysts. On March 2, 2026, AIM ImmunoTech announced entering into an agreement with the PPD clinical research business of Thermo Fisher Scientific (TMO) to design a pivotal Phase 3 clinical trial for Ampligen. The study will […]
Are Medical Stocks Lagging AIM ImmunoTech (AIM) This Year?
Here is how AIM ImmunoTech Inc. (AIM) and Cullinan Therapeutics (CGEM) have performed compared to their sector so far this year.
AIM ImmunoTech Files Preliminary Prospectus for Rights Offering
AIM ImmunoTech (AIM) on Friday filed a preliminary prospectus with the US Securities and Exchange Co